FDA Drug Recalls

Recalls / Class II

Class IID-0296-2015

Product

ONDANSETRON INJECTION, USP, 4 mg/ 2 mL (2 mg/mL), For IM or IV Use, Single Dose 2 mL Vials, Rx only. APP Pharmaceuticals, LLC, Schaumburg, IL 60173. NDC: 63323-373-02

Brand name
Ondansetron
Generic name
Ondansetron Hydrochloride
Active ingredient
Ondansetron Hydrochloride
Route
Intramuscular, Intravenous
NDCs
63323-373, 63323-374
FDA application
ANDA076972
Affected lot / code info
Lot 6003930, exp. date 04/2014

Why it was recalled

Lack of Assurance of Sterility: Glass vials may have finish fractures and glass particles.

Recalling firm

Firm
Fresenius Kabi USA, LLC
Notification channel
Letter
Type
Voluntary: Firm initiated
Address
3 Corporate Dr, N/A, Lake Zurich, Illinois 60047-8930

Distribution

Quantity
184,550 Vials
Distribution pattern
U.S. Nationwide Including Puerto Rico

Timeline

Recall initiated
2012-09-27
FDA classified
2014-12-10
Posted by FDA
2014-12-17
Terminated
2014-12-12
Status
Terminated

Source: openFDA Drug Enforcement endpoint. Recall record D-0296-2015. The FDA issues recall classifications as health-hazard assessments, not legal findings; for legal claims consult a licensed attorney.

Class II recall: Ondansetron · FDA Drug Recalls